<SEC-DOCUMENT>0001193125-21-175778.txt : 20210527
<SEC-HEADER>0001193125-21-175778.hdr.sgml : 20210527
<ACCEPTANCE-DATETIME>20210527215243
ACCESSION NUMBER:		0001193125-21-175778
CONFORMED SUBMISSION TYPE:	S-1MEF
PUBLIC DOCUMENT COUNT:		7
<REFERENCE-462B>333-255393
FILED AS OF DATE:		20210527
DATE AS OF CHANGE:		20210527
EFFECTIVENESS DATE:		20210527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Centessa Pharmaceuticals plc
		CENTRAL INDEX KEY:			0001847903
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1MEF
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256581
		FILM NUMBER:		21975766

	BUSINESS ADDRESS:	
		STREET 1:		THE DOROTHY HODGKIN BUILDING
		STREET 2:		BABRAHAM RESEARCH CAMPUS
		CITY:			BABRAHAM, CAMBRIDGE
		STATE:			X0
		ZIP:			CB22 3FH
		BUSINESS PHONE:		44 (0)7767 003904

	MAIL ADDRESS:	
		STREET 1:		THE DOROTHY HODGKIN BUILDING
		STREET 2:		BABRAHAM RESEARCH CAMPUS
		CITY:			BABRAHAM, CAMBRIDGE
		STATE:			X0
		ZIP:			CB22 3FH

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Centessa Pharmaceuticals Ltd
		DATE OF NAME CHANGE:	20210224
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1MEF
<SEQUENCE>1
<FILENAME>d123754ds1mef.htm
<DESCRIPTION>S-1MEF
<TEXT>
<HTML><HEAD>
<TITLE>S-1MEF</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on May 27, 2021. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>
</B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF&nbsp;1933 </I></B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:1pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CENTESSA PHARMACEUTICALS PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>England and Wales<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834<BR></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable<BR></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction of<BR>Incorporation&nbsp;or&nbsp;Organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Centessa Pharmaceuticals plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>3rd Floor, 1 Ashley Rd, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Altrincham, Cheshire, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>United Kingdom, WA14 2DT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+44 7391 789784 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#146;s Principal Executive Offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Saurabh Saha </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Centessa Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>5 Walnut Grove Drive, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Suite 120 Horsham, PA 19044 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+1 (267) 609-7550 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+1
(617)-468-5770 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B><I>&nbsp;&nbsp;Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Mitchell&nbsp;S.&nbsp;Bloom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Edwin M. O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>James Xu<BR>Goodwin&nbsp;Procter&nbsp;LLP<BR>100 Northern Avenue<BR>Boston, MA
02210<BR><FONT STYLE="white-space:nowrap">(617)&nbsp;570-1000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Graham&nbsp;Defries<BR>Goodwin&nbsp;Procter (UK)&nbsp;LLP<BR>100 Cheapside<BR>London&nbsp;EC2V&nbsp;6DY<BR>United Kingdom<BR>+44 20 7447 4200</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Iqbal Hussain<BR>Centessa</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Pharmaceuticals</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>plc<BR></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>3rd Floor, 1
Ashley Rd,</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Altrincham, Cheshire,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>United&nbsp;Kingdom,&nbsp;WA14&nbsp;2DT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Joshua&nbsp;A.&nbsp;Kaufman<BR>Divakar Gupta<BR>Geoffrey R. Starr<BR>Cooley LLP<BR>55 Hudson
Yards<BR>New&nbsp;York,&nbsp;New&nbsp;York</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>10001</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Claire&nbsp;A.&nbsp;Keast-Butler</FONT><BR>Cooley (UK) LLP<BR>22
Bishopsgate<BR>London EC2N 4BQ</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>United Kingdom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+44 20 7583 4055</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>+44 7391 789784 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Approximate
date of commencement of proposed sale to the public: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>As soon as practicable after the effective date of this registration
statement. </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to
Rule&nbsp;415 under the Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9746; (333-255393) </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">Non-Accelerated Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;Growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Title of each class of securities<BR>to be registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount to be<BR>registered(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed maximum<BR>offering price<BR>per share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed maximum<BR>aggregate<BR>offering price(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>registration fee(3)</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Ordinary shares, nominal value &pound;0.002 per
share(4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">1,725,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$20.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$34,500,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center">$3,764</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">In accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended, an additional amount
of securities having a proposed maximum aggregate offering price of no more than 20% of the maximum aggregate offering price of the securities eligible to be sold under the related Registration Statement on Form S-1, as amended (File No. 333-255393)
(the &#147;Prior Registration Statement&#148;), is hereby being registered. Represents only the additional number of shares being registered and includes 258,750 additional shares the underwriters have the option to purchase. Does not include the
securities that the registrant previously registered on the Registration Statement on Form S-1 (File No. 333-255393). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Includes the aggregate offering price of 258,750 additional ordinary shares represented by ADSs that the
underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(a) under the Securities Act of 1933, as amended. The registrant previously
registered securities on the Prior Registration Statement at an aggregate offering price not to exceed $345,000,000, which was declared effective by the Securities and Exchange Commission on May 27, 2021. In accordance with Rule 462(b) under the
Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $34,500,000 is hereby registered, which includes shares issuable upon the exercise of the underwriters&#146; option to purchase additional
shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">These ordinary shares are represented by ADSs, each of which represents one ordinary share of the registrant.
ADSs issuable upon deposit of the 1,725,000 ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form <FONT STYLE="white-space:nowrap">F-6</FONT> (File No.&nbsp;333-256385), including any amendments
thereto. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman"><B>The Registration Statement shall become effective upon filing in accordance with Rule&nbsp;462(b) promulgated under the Securities Act of
1933, as amended. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE AND INCORPORATION OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), Centessa Pharmaceuticals plc (the
&#147;Registrant&#148;) is filing this Registration Statement on Form&nbsp;S-1 (this &#147;Registration Statement&#148;) with the Securities and Exchange Commission (the &#147;Commission&#148;). This Registration Statement relates to the public
offering of securities contemplated by the Registration Statement on&nbsp;Form&nbsp;S-1, as amended (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-255393)</FONT> (the &#147;Prior Registration Statement&#148;), which the Registrant originally
filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/0001847903/000119312521123969/d123754ds1.htm">April 21, 2021</A>, and subsequently amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1847903/000119312521159305/d123754ds1a.htm">May&nbsp;12,
 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1847903/000119312521170068/d123754ds1a.htm">May&nbsp;24, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1847903/000119312521173367/d123754ds1a.htm">May 26, 2021</A>, and which
the Commission declared effective on May&nbsp;27, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant is filing this Registration Statement for the sole purpose of
increasing the aggregate number of American Depositary Shares (&#147;ADSs&#148;), each representing a single ordinary share of the Registrant, offered by the Registrant by 1,725,000 ADSs, 258,750 of which are subject to purchase upon exercise of the
underwriters&#146; option to purchase additional ADSs of the Registrant. The additional shares that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering
price set forth in the Calculation of Registration Fee table contained in the Prior Registration Statement. The information set forth in the Prior Registration Statement, including all amendments and exhibits thereto, are incorporated by reference
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit<BR>number</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1 </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d123754dex51.htm">Opinion of Goodwin Procter (UK)&nbsp;LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d123754dex231.htm">Consent of KPMG LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d123754dex232.htm">Consent of KPMG LLP, independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d123754dex233.htm">Consent of Frazier&nbsp;&amp; Deeter, LLC, independent auditors. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d123754dex51.htm">Consent of Goodwin Procter (UK)&nbsp;LLP (included in Exhibit&nbsp;5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1847903/000119312521123969/d123754ds1.htm#poa">Power of Attorney (previously filed on the signature page to the Registrant&#146;s Registration Statement on Form S-1 (File No. 333-255393),
 originally filed with the Securities and Exchange Commission on April 21, 2021 and incorporated by reference herein.) </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, under the laws and regulations of England and Wales, on May&nbsp;27, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CENTESSA PHARMACEUTICALS PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/&nbsp;&nbsp;Saurabh Saha, M.D., Ph.D</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Saurabh Saha, M.D., Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: <I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="poa"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and
on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Date</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Saurabh Saha, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Saurabh Saha, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">May&nbsp;27,&nbsp;2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Gregory Weinhoff, M.D., M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gregory Weinhoff, M.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer (Principal Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Marella Thorell</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Marella Thorell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Accounting Officer (Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Francesco De Rubertis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arjun Goyal, M.D., M.Phil, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Aaron Kantoff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brett Zbar, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mary Lynne Hedley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Samarth Kulkarni, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Carol Stuckley, M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carol Stuckley, M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert Califf, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Title</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Date</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Gregory Weinhoff, M.D., M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gregory Weinhoff, M.D., M.B.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authorized Representative in the United States</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">May&nbsp;27,&nbsp;2021</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Power of Attorney </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD>
<TD HEIGHT="10" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Gregory Weinhoff, M.D., M.B.A.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attorney-in-Fact</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d123754dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter (UK) <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100
Cheapside</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London EC2V 6DY</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+44 (0) 20 7447 4200</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27&nbsp;May 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa
Pharmaceuticals plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3rd Floor 1 Ashley Rd, Altrincham, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom, WA14 2DT </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Centessa Pharmaceuticals plc &#150; Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> &#150; Exhibit 5.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as English legal advisers to Centessa Pharmaceuticals plc, a public limited company incorporated in England and Wales with company number
12973576 (the &#147;<B>Company</B>&#148;), in connection with the proposed offering of American Depositary Shares (the &#147;<B>ADSs</B>&#148;) representing ordinary shares of nominal value &pound;0.002 each in the capital of the Company (the
&#147;<B>Ordinary Shares</B>&#148;) (the &#147;<B>Offering</B>&#148; and the Ordinary Shares allotted and issued in connection therewith to Citibank, N.A. as the custodian and represented by ADSs, being the &#147;<B>Shares</B>&#148;). Each ADS
represents one Ordinary Share. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><U>1.</U></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>INTRODUCTION</U> </B></P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Purpose </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the preparation and filing of (i)&nbsp;a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
No.<U></U><FONT STYLE="white-space:nowrap">&nbsp;333-255393)</FONT> (such registration statement, as amended or supplemented through the date hereof, the &#147;<B>Initial Registration Statement</B>&#148;) and (ii)<U></U>&nbsp;a second Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed pursuant to Rule 462(b) promulgated under the U.S. Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;) for the offering of additional ADSs representing
additional Ordinary Shares, to which this letter is attached as an exhibit (the<U></U>&nbsp;&#147;<B>462(b) Registration Statement</B>&#148;, and, together with the Initial Registration Statement, the &#147;<B>Registration Statement</B>&#148;)
including a prospectus (the &#147;<B>Prospectus</B>&#148;) with the U.S. Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) pursuant to the Securities Act, we have been asked to provide opinions on certain matters, as set out below. We
have taken instruction in this regard solely from the Company. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Defined terms and headings</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this letter: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">capitalised terms used without definition in this letter or the schedules hereto have the meanings assigned to
them in the Registration Statement unless a contrary indication appears; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">headings are for ease of reference only and shall not affect interpretation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Legal review</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the purpose of issuing this letter, we have examined such questions of law as we have considered appropriate. We have reviewed the
following documents and conducted only the following enquiries and searches: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an online search at Companies House in respect of information available for inspection on the Company&#146;s
file conducted on 27&nbsp;May 2021 at 4:08 pm (UK time); </P></TD></TR></TABLE> <P STYLE="font-size:36pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Goodwin Procter (UK) LLP
is a limited liability partnership registered in England and Wales with registered number OC362294. Its registered office is at 100&nbsp;Cheapside, London, EC2V 6DY. A list of the names of the members of Goodwin Procter (UK) LLP is available for
inspection at the registered office. Goodwin Procter (UK) LLP is authorised and regulated by the Solicitors Regulation Authority. Goodwin Procter (UK) LLP is affiliated with Goodwin Procter LLP, which operates in the United States of America. </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an enquiry of the Central Index of Winding Up Petitions, London on 27&nbsp;May 2021 at 3:57 pm (UK time) ((a)
and (b)<U></U>&nbsp;together, the &#147;<B>Searches</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certificate dated 27&nbsp;May 2021 signed by the Chief Executive Officer of the Company (the
&#147;<B>Certificate</B>&#148;) relating to certain factual matters as at the date of the Certificate and having annexed thereto copies (certified by the Chief Executive Officer of the Company as being true, complete, accurate and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> in each case) of the following documents: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a PDF copy of the print of the resolutions passed by the shareholders of the Company at a general meeting held
on 20&nbsp;May 2021, approving, <I>inter alia, </I>the allotment of shares by the directors, or the granting of rights to subscribe for, or to convert any security into, shares on a non-preemptive basis up to an aggregate nominal amount of
&pound;305,000 (the &#147;<B>Shareholder Resolutions</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a PDF copy of the minutes of a meeting of the board of directors of the Company dated 20&nbsp;May 2021 pursuant
to which it was resolved, <I>inter alia</I>, to carry out the share capital reorganisation, in the case of the redesignation and conversion conditional on, but effective immediately prior to, the Offering and to establish a pricing committee of the
board of directors of the Company (the &#147;<B>Pricing Committee</B>&#148;) and to delegate authority to the Pricing Committee to allot the Shares and to approve the nominee and depositary transfers in connection with the Offering and the use of
the Company&#146;s seal (the &#147;<B>Board Resolutions</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a PDF copy of the consent of an Investor Majority (as defined in the Articles (as defined below)) dated
20&nbsp;May 2021, pursuant to which an Investor Majority approved, <I>inter alia</I>, the Offering and the adoption of the IPO Articles (as defined below) (the &#147;<B>Investor Majority Consent</B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the class consents from the holders of the A preferred shares and A ordinary shares of the Company
dated 20&nbsp;May 2021 approving, amongst other things, the conversion of all classes of shares in the Company into a single class of ordinary shares (the <B>&#147;Class</B><B><U></U></B><B>&nbsp;Consents&#148;</B>); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a draft PDF copy of the minutes of the meeting of the Pricing Committee authorising, <I>inter alia</I>, the
allotment of the Shares and the nominee and depositary transfers in connection with the Offering (the &#147;<B>Pricing Committee Minutes</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vi.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a PDF copy of the current articles of association of the Company adopted pursuant to a special resolution dated
10&nbsp;May 2021 (the &#147;<B>Articles</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">vii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">PDF copies of (a)&nbsp;the certificate of incorporation of the Company dated 26&nbsp;October 2020 and
(b)&nbsp;the certificate of incorporation on <FONT STYLE="white-space:nowrap">re-registration</FONT> of the Company as a public limited company dated 14&nbsp;May 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a draft copy of the articles of association of the Company to be adopted conditional on the completion of the
Offering pursuant to a special resolution passed pursuant to the Shareholder Resolutions (the &#147;<B>IPO Articles</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the Registration Statement (including the Prospectus). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Applicable law</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This letter, the opinions given in it, and any <FONT STYLE="white-space:nowrap">non-contractual</FONT> obligations arising out of or in
connection with this letter and/or the opinions given in it, are governed by, and to be construed in accordance with, English law and relate only to English law as applied by the English courts, including the laws of the European Union to the extent
having the force of law in England, as at today&#146;s date. In particular: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we have not investigated the laws of any country other than England and we express no opinion in this letter on
the laws of any jurisdiction other than England and we assume that no foreign law would or might affect any of the opinions given below. It is assumed that no foreign law which may apply to the matters contemplated by the Registration Statement
(including the Prospectus), the Offering, the Company, any document or any other matter contemplated by any document would or might affect this letter and/or the opinions given in it; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we do not undertake or accept any obligation to update this letter and/or the opinions given in it to reflect
subsequent changes in English law or factual matters. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assumptions and reservation</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The opinions given in this letter are given on the basis of each of the assumptions set out in schedule 1 (<I>Assumptions</I>) and are subject
to the reservation set out in schedule 2 (<I>Reservation</I>) to this letter. The opinions given in this letter are strictly limited to the matters stated in paragraph 2 (<I>Opinions</I>) below and do not extend, and should not be read as extending,
by implication or otherwise, to any other matters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OPINIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Subject to paragraph 1 (<I>Introduction</I>) and the other matters set out in this letter and its schedules, and subject further to the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Registration Statement becoming effective under the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Shares to be allotted and issued in connection with the Offering not being greater than
18,975,000 and such Shares being allotted and issued by 2&nbsp;June 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the receipt in full of payment for the Shares in an amount of &#147;cash consideration&#148; (as defined in
section 583(3) of the Act) of not less than the aggregate nominal value for such Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">valid entries having been made in relation to the allotment and issue of the Shares in the books and registers
of the Company, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">it is our opinion that, as at today&#146;s date, the Shares, if and when allotted and issued, registered
in the name of the recipient in the register of members of the Company and delivered as described in the Registration Statement, will be duly and validly authorised and issued, fully paid or credited as fully paid (subject to the receipt of valid
consideration by the Company for the issue thereof in connection with the Offering) and will not be subject to any call for payment of further capital. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>EXTENT OF OPINIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to any agreement, instrument or other document other than as specified in this letter or as to any liability to tax or
duty which may arise or be suffered as a result of or in connection with the Offering or the transactions contemplated thereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This
letter only applies to those facts and circumstances which exist as at today&#146;s date and we assume no obligation or responsibility to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our
attention, any changes in laws which may occur after today, or to inform the addressee of any change in circumstances happening after the date of this letter which would alter our opinion. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISCLOSURE AND RELIANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This letter is addressed to you in connection with the Registration Statement. We consent to the filing of this letter as an exhibit to the
Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules<U></U>&nbsp;and regulations thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Other than for the purpose set out in the prior paragraph, this letter may not be relied upon, or assigned, for any purpose, without our prior
written consent, which may be granted or withheld in our discretion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter (UK) LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Goodwin Procter (UK) LLP
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSUMPTIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions in this letter
have been given on the basis of the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures, stamps and seals on all documents, the authenticity and completeness of all
documents submitted to us as originals, and the conformity to original documents of all documents submitted to us as copies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, where a document has been examined by us in draft or specimen form, it will be or has been duly executed
in the form of that draft or specimen, and that each of the signed documents examined by us has been duly executed and, where applicable, delivered on behalf of the Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Articles referred to in paragraph 1.3(c) of this letter remain in full force and effect, and, save for
the adoption of the IPO Articles upon the Offering, no alteration has been made or will be made to such articles of association, in each case prior to the date of the allotment and issue of the Shares (the &#147;<B>Allotment Date</B>&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the Allotment Date the Company will comply with all applicable laws to allot and issue the Shares and the
Company will receive such amounts as are necessary to fully pay the nominal value of the Shares and any applicable share premium; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that all documents, forms and notices which should have been delivered to the Registrar of Companies in respect
of the Company have been so delivered, that information revealed by the Searches was complete and accurate in all respects and has not, since the time of the Searches, been altered and that the results of the Searches will remain complete and
accurate as at the date of the Registration Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the contents of the Certificate were true and not misleading when given and remain true and not misleading
as at the date of this letter and there is no fact or matter not referred to in the Certificate which could make any of the information in the Certificate inaccurate or misleading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that in relation to the allotment and issue of the Shares, the directors of the Company have acted and will act
in the manner required by section 172 of the Companies Act (Duty to promote the success of the Company), and there has not been and will not be any bad faith, breach of trust, fraud, coercion, duress or undue influence on the part of any of the
directors of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on or around the date of this letter and prior to the issue of the Ordinary Shares, the Company will validly
enter into an underwriting agreement on substantially the terms and conditions described in Exhibit 1.1. of the Registration Statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Company is not, nor will be, engaging in criminal, misleading, deceptive or unconscionable conduct or
seeking to conduct any relevant transaction or any associated activity in a manner or for a purpose which might render any transaction contemplated under any corporate approvals or any associated activity illegal, void or voidable; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Pricing Committee Minutes referred to in paragraph 1.3(c) of this letter are executed in substantially
the form provided to us annexed to the Certificate. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g123754g13w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESERVATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions in this letter
are subject to the following reservation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the opinions set out in this letter are subject to: (i)&nbsp;any limitations arising from applicable laws
relating to insolvency, bankruptcy, administration, reorganisation, liquidation, moratoria, schemes or analogous circumstances; and (ii)&nbsp;an English court exercising its discretion under section 426 of the Insolvency Act 1986 (<I><FONT
STYLE="white-space:nowrap">co-operation</FONT> between courts exercising jurisdiction in relation to insolvency</I>) to assist the courts having the corresponding jurisdiction in any part of the United Kingdom or any relevant country or territory.
</P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d123754dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated March&nbsp;12, 2021, except as to Note 8, which is as of May&nbsp;24,&nbsp;2021, with respect to the balance sheet
of Centessa Pharmaceuticals Limited as of December&nbsp;31, 2020, the related statements of operations and comprehensive loss, shareholders&#146; deficit, and cash flows for the period October&nbsp;26, 2020 (inception) through December&nbsp;31,
2020, and the related notes, incorporated herein by reference and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;27, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d123754dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centessa Pharmaceuticals plc: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated March 12, 2021, with respect to the combined balance sheets of the Centessa Predecessor Group (consisting of Z
Factor Limited, LockBody Therapeutics Ltd, and Morphogen-IX Limited) as of December 31, 2019 and 2020, the related combined statements of operations and comprehensive loss, convertible preferred shares and combined deficit, and cash flows for the
years then ended, and the related notes, incorporated herein by reference and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May 27, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>d123754dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g123754g69r58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT AUDITOR </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of Centessa Pharmaceuticals plc pursuant to Rule
462(b) of the Securities Act of 1933 of our reports dated March&nbsp;12, 2021, relating to the financial statements of Palladio Biosciences, Inc.; Inexia Limited; Janpix Limited; Pega-One S.A.S.; PearlRiver Bio GmbH; Orexia Limited; Capella
Bioscience Limited; and ApcinteX Limited, appearing in the Prospectus, which is part of this Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to
us under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Frazier&nbsp;&amp; Deeter, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tampa, Florida </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;27, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g123754g13w08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g123754g13w08.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M.:0VB":YCN)5X=X\8)KZ&G?E]YW9\U4LI.RLBU6A $XH @GO;6U(%Q<PQ$]
M\@7/YT 2I(DB!XV5D/0J<@T +F@"NNH63S>2EW TN<;!*"WY4 6<XXH 0L%!
M)(  ZF@"O%J%G<2F*"[AED'54D!(_ &@"SF@"H=5TY25-_; @X(,J_XT 3Q7
M$-PFZ"5)5]48$?I0 R6\MH)%CEN(HW;[JNX!/TS0!,6"J6)P!U)XQ0!%!=07
M*EK>>.50<$HP;'Y4 $MW;P2)'-<11N_W5=P"?I0 /=6\<ZP//&LK?=0N Q_"
M@ FN[>W=4FGCC9ONAW )^F: )0<T 1P75O<,ZPSQR%/O!'!V_7'XT")Z8'+>
M/6VZ' ?^GE?_ $%J\W,OX2]?T9ZN5?QGZ?JCD_#+Y\160S_'_0UY6#7[^)ZV
M.5L/)GJ6*^FV/E3F]7\9:?I;/%%FYN%X*)P%/N:XZN,IT]%JST,/EU:LN9Z(
MX+6/%FK:KN5IC! ?^6<1P/Q/4UY\\54J;NQ[^'R^A1U2N_,Z[X:C&B77_7P?
M_017=@O@9Y.<_P =>AVE=QXQQOQ(\52^%O#GF6A O;E_*B)&=G&2WY=/<T <
MMH?PDCU:Q34?$VH7<M]<*'*JXRF>>20<GUH Z'PEX"N?">N3S0:U-+I;1_):
MMW8]V[<=B,4 <]XVU;5O$_C./P7HUP;:!1_I,BDC=QDY([ =NYH M2?!+2!8
MD0:E>+>@9$S;=N[_ '0,X_&@!WPW\1:K!KE]X0UR1I;FT#&*1FR< \KGN,$$
M&@#)UFXU;XC^.;KP_97;6ND6)(E*]\'!)'?)X H T;_X+V,5EYNCZC=Q:A&-
MR-(P*L1TZ %?K0!I?"[Q5>ZU:WFDZLQ?4-/(!=OO,N<<^X((SWH X7P;X+TW
MQ?K_ (@74)+B,6\Y*>0P&<NV<Y!]* -+Q+X(O?A_"OB#PUJ<XA@<>='(<D G
M&3@ ,,X!X[T 3?$)QXF\!:)XMMH_+G@8>8!U3)P?R=: .I\2^*5_X5.VKQ.!
M+>VJQI_ON,'\OF_*@#D_A!//HWB&_P!!O$,37$"7,:GZ _JK#\J +4\8\5_'
M!8R ]IHZ D=LJ,_^AL/RH =XG _X7KH)Q_!'_P"ST 4OC7#)/KNAQ0J6F>-E
M0#J26&,4 =9\-?&;:_IS:;J#;=6LAM<-P9%'&[ZCH:!&-\'1C5_%G_7Q'T_W
MI: /5Z8'(_$1MOA^W/\ T]+_ .@M7!CU>DO7_,]?*/X[]/U1QWA23/B6Q&?X
M_P"AKS,*K5HGKY@O]GD>N<U]"?(GELWAK4]3UJ\$-L4C\]_WDGRJ!GMZUX"P
MU6I5E9:'U4<;1HT8W>MD8^NZ.^B:B;1Y5E.P/N48Z_\ ZJFI2=*7*SKPN(^L
MT^=*QW/PW_Y ES_U\'_T$5Z6!^!GAYQ_'7H=D:[SQSSGXQ:-<ZCX:M[ZV5G-
MA*7=0,G81@G\,#]: )]/\9:+XK\'O:-K<6D7SP".0O($:)NY4DC(],&@#E?!
MMS+!\4H]-M_$EQK%DL+GS&D)5FV\\9(X/>@"379W\"_%W^W;J%VTV_!RZC.,
M@!OQ! ./2@#T.7QSX8@T\WAUJT:+&0J2 N?8+US^% '!?#U+CQ-\1=5\6>2T
M5F R1Y'4G  ]R%'/UH J:7?I\.OB;JD&JHT>GZ@2R38R I;<K?09(/I0!Z)J
MGCWPWIFFM>G5;:X.W*102!W<^@ Z?4XH X_X0V%W<WNL>)KJ,QI?.5C_ -K+
M%F(]N@H H_##5+#3?$/B8WU[;VH>;Y//E5-V'?.,_6@#3^)?C?2;CP[-HFF7
M*7UW>%4(@.\*H(/4=3QC'/6@#>T3PHZ_"]/#]X,336S;@?X'8EA^1(_*@#R'
M2KF[UV#0_!4BN!#J#M)GLO<8]OG_ #H [CXB'_A%?&N@^*+>+$04PRJO&0O;
M\58_E0!>^$&GR-IVI>(+D9N-1N&P3U*@DG\V)_*@#/\ $W_)=-!_W(__ &>@
M ^*9QXX\*'_IHO\ Z,6@!?B)X=N] UF+QKH(V21N&NE4<9_O8[@C@_G0(3X)
M3FYN_$LY4*97A<@=!DR'% 'KM,#E?'UE<WN@PI;1-(R7"NVT9PNUAG]17%C4
M_9:(]7*JD*==N;MI^J//[ 2:9=QW43XFB.03TS]*\&->49*4>A]!6M6@X/9G
M<Z=XXA<!-1A,3#^-.5/U'45ZM',8O^(K'A5LKFG>D[C-3\=V\2E-.A,SXX=^
M%'X=33J9C%:4U<=#*IMWJNQP>IWUUJ=VUS=/YDS<<# 'L*\Z52527-+<]ZA1
MA0AR0V/1/ -E<6>AR&>,Q^;*74,,'& .GX5[&#C*-/5'SN:585*_NN]D=57:
M>6(5!!!&1Z4 <=J/PM\*:C<FX:Q:!R<D02%%/X=!^% &OH7A+1/#:G^R[!(9
M",&4DLY'^\>: +^I:38ZQ9M::A:QW$#?PN,X]QZ&@#DD^$?A%+CS?L<S+G_5
MM.Q6@#LK.RMM/M8[6S@C@@C&%CC7 % %36- TO7[46^J6:7$8Y7=P5/L1R*
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MSL=+\,:;I8#10B28?\M).3^'85ZU+"TZ6RU/%KXVM7^)V1LXQ72<@M !0 E
M"_A0 E "T % !0 4 % !0 E "T )0 4 +0 E "T %  *8A: "@!#2 0]13&-
M[BDMB);H>.IIE=!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
'@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g123754g69r58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g123754g69r58.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0"$17AI9@  34T *@    @ !P$2  ,
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M .: "BBC- !111G% !5/P]_R +'_ *]X_P#T$5<JGX>_Y %C_P!>\?\ Z"*
M+E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6-\1/^#<?XD?#;P!K7B*Z^(_@FXMM#L)]0EBCL;D/(D,;2%5)XR0N!FOTO\
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M9_$.\UJ6S\.:;X9;2H(/%%]I45N9K28S$)!-&&W>6A)(.,>]>M>"_P#@F?\
M 7PIXQTG5M*'B!M4TJ\BO+,-X\U6X7SHW#IF-KHJXW*,JP((X((KS#1/V1_A
MI^U7_P %3/VC(_B)X+T3Q<NB:9X6-@-1A\S[)YEG/YFSD8W;$S_NBO=_ ?\
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M_P $V_AOXJT_4/&DW@J^MH[#PW:ZM%]O\2ZU/++((K98H<^=<.P; 7@*,D@
MD>J_!#]FGP;^R7^SQ=^#_!=MY=I#:W%S=W4TWGWVK73H3+=7,I^:69VY9C[
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M[Q)\)_C/#X@NHEBOM5L/ _B329KN-!@?:'M5C,H4<?O-V ,=*]5_X+ 3K/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _%5Q8ZZ_B;QGI>K:QJ&COH=C?67AU;2*&W))W7-M+//%<2ECEBJQ1D%E$:
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M-+ QMN=MV-H.X;?IWKU3'S4 !&IQKNPM&=.FH3ES/75EQ32LPHHHKJ&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
D0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
